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Introduction
The CCCTC-binding factor (CTCF), best known as a
versatile transcription factor and chromatin insulator
(reviewed in [1]), has been suggested as a risk factor in
familial breast cancer, possibly acting as a tumour
suppressor. The gene was mapped to 16q22–24, a
region frequently showing loss of heterozygosity (LOH) in
sporadic and familial breast cancer [2–4], and LOH of this
region has been shown to correlate to increased survival
and late distant metastasis [4–6]. A tumour-specific
rearrangement of CTCF exons was first reported in one
primary breast cancer patient [7], and four additional
CTCF somatic mutations were subsequently observed in
a set of 130 cases of breast, prostate and Wilms tumours
in another study [8].
Skewed X inactivation denotes that the choice of which of
the two X chromosomes is inactivated in females is non-
random [9]; it has been implicated in cancer development.
In a study of patients with ovarian cancer, a higher
frequency of skewed X inactivation was found in patients
with invasive cancer than in patients with borderline
cancer and healthy controls [10]. It was also found that
young patients with breast cancer have a higher frequency
of skewed X inactivation in blood cells than controls of the
same age [11]. This finding indicated that skewed X
inactivation might be a risk factor in breast cancer
development, and suggested the involvement of as yet
unknown X-linked genes, or genetic factors involved in the
X inactivation process in the development of breast
cancer in young females. Recently, CTCF was shown to
be a candidate trans-acting factor for X inactivation choice
[12], suggesting that it might therefore have a role in
breast development.
In the present study we investigated CTCF for germline
mutations in 153 cases from 139 non-BRCA1/BRCA2
breast cancer families to determine whether CTCF
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Abstract
Introduction: The CCCTC-binding factor (CTCF), known as a
versatile transcription factor and chromatin insulator and to be
involved in X inactivation, has also been suggested to be a
tumour suppressor on 16q. We investigated 153 patients with
familial non-BRCA1/BRCA2 breast cancer for germline
mutations in the CTCF gene.
Methods: Mutation screening of CTCF was performed by
denaturing high-performance liquid chromatography followed
by cycle sequencing.
Results: We found two sequence variants, 240G→A in the 5′
untranslated region and 1455C→T (S388S) in exon 4, in five
familial breast cancer cases. Three of these five cases had both
variants. Cases and controls showed the same prevalence for
the two variants, which were found in linkage disequilibrium in
most cases and controls.
Conclusion: The present study suggests that germline
mutations in CTCF are not important as a risk factor for breast
cancer.
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mutations could have a role in breast cancer pre-
disposition. Of the 139 families, 28 had previously been
included in a genome-wide linkage analysis. The linkage
analysis results showed that all the 28 families could share
a putative predisposing gene in 16q22–24 (Luo et al.,
unpublished data). In addition, 26 tumours from 26 of the
139 families included in the present study had previously
been analysed for LOH [13]. Of the 26 tumours analysed,
16 were informative for at least one microsatellite marker
at 16q. Only three tumours showed LOH at 16q and were
investigated for germline mutations in the E-cadherin
gene, and no pathogenic mutation was found [14]. Thus




For  CTCF analysis, 153 breast cancer patients were
recruited from 139 families. In our previous genome-wide
linkage analysis, 28 of the families were shown to share a
common haplotype in 16q22–24, where the CTCF gene
resides. All the families included were recruited through a
clinicogenetic counselling procedure and were considered
BRCA1 and BRCA2 negative [15,16]. In total, 90 cases
were ascertained from high-risk families in which there
were three or more first-degree affected relatives with
breast cancer over at least two generations. The mean
number of cases in each family was 3.3 and the mean age
of diagnosis was 53 years of age. The other 63 cases
were ascertained from low-risk families in which there
were only two first-degree affected relatives with breast
cancer, with a mean age of onset of 47 years. All the
cases in this study were included in accordance with
guidelines approved by the Ethics Committee at Karolinska
Institutet. As control population we used 190 unrelated
healthy relatives of patients recruited at Department of
Clinical Genetics, Karolinska Hospital.
Denaturing high-performance liquid chromatography
(DHPLC)
DHPLC analysis was performed with automated instrumen-
tation equipped with a DNASep column, the Wave®
nucleic acid fragment analysis system (Transgenomic,
Santa Clara, CA), on the reverse transcriptase polymerase
chain reaction (RT–PCR) product. The entire coding
sequence of the gene CTCF was divided into six
overlapping fragments; the primers used for RT–PCR
amplification of each segment are given in Table 1. Total
RNA of each sample was extracted from EBV-transformed
lymphocytes using TRIzol® Total RNA Isolation Reagent
kit (Invitrogen, Carlsbad, CA) and was reverse transcribed
with random hexamers using the GeneAmp® RNA PCR kit
(PE Biosystems, Foster City, CA) to generate cDNA. A
2 µl aliquot of cDNA was used in PCR amplification in
50 µl reaction volumes containing 10 pmol of sense and
antisense primers for each fragment, 1.5 mM MgCl2,
100 µM dNTPs, 1.25 U of AmpliTaq Gold polymerase (PE
Biosystems) and 1 × PCR buffer supplied by the
manufacturer. A universal Touchdown PCR protocol was
employed to improve PCR specificity and to minimize
PCR optimization. It consisted of an initial incubation of
95°C for 10 min, a first round of 6 cycles of 95°C for 30 s,
58°C for 45 s with 1°C decrement per cycle, 72°C for
45 s, a second round of 26 cycles of 95°C for 30 s, 53°C
for 45 s, 72°C for 45 s, and a final extension step of 72°C
for 7 min. PCR products were then denatured at 95°C for
5 min and cooled slowly in a PCR instrument at a rate of
1.5°C per cycle for 40 cycles. Each PCR product (10 µl)
was then loaded on the Wave® instrument and eluted with
a linear acetonitrile gradient consisting of buffer A (0.1 M
triethylamine acetate; TEAA) and buffer B (0.1 M TEAA in
25% acetonitrile) at a constant flow rate of 0.9 ml/min.
Specific values of the gradient ranges and the column
temperature required for optimal resolution of each
amplicon were determined by the WaveMaker software
(Transgenomic) based on the sequence. A Mutation
Standard (Transgenomic) was run with the samples
analysed, to ensure the best performance of the DHPLC
instrument for mutation detection. The elution profiles
were recorded and analysed by HSM 7000 software
(Transgenomic).
Cycle sequencing
Samples with an altered DHPLC profiles were reamplified
and purified with QIAEX II gel extraction kit (Qiagen,
Hilden, Germany). The bi-directional sequencing reaction
was performed with ABI PRISM® BigDye™ Terminator
Cycle Sequencing Ready Reaction Kits version 2.0 (PE
Biosystems) in accordance with the manufacturer’s instruc-
tions, with the primers used in RT–PCR amplification as
sequencing primers (Table 1).
Pyrosequencing
Pyrosequencing was adopted in this study to determine
the frequency of the CTCF variants found in familial breast
cancer cases in normal controls. Primers used in the
pyrosequencing analysis are listed in Table 2. The
conditions of PCR amplification were the same as those
used in the DHPLC analysis except that genomic DNA
rather than cDNA was used as template and the number
of cycles was increased from 35 to 50. Biotin-labelled
amplicons (30 µl) were mixed with 25 µl of BW buffer
(10 mM Tris-HCl, 2 M NaCl, 1 mM EDTA and 0.1 Tween 20,
pH 7.6) and immobilized on 20 µl of streptavidin-coated
super paramagnetic beads (Dynabeads®, M-280–strepta-
vidin; Dynal AS, Oslo, Norway) by incubation at 65°C for
15 min, with shaking. Single-stranded DNA was obtained
by incubating the immobilized amplicons in 50 µl of 0.5 M
NaOH for 5 min using a PSQ 96 Sample Prep Tool
(Pyrosequencing AB, Uppsala, Sweden). Each sample
(well) was washed twice with 100 µl of 1 × annealing
buffer (200 mM Tris acetate and 50 mM magnesiumR189
acetate). The immobilized strand was resuspended in
45 µl of 1 × annealing buffer containing 2 pmol of sequenc-
ing primer. Hybridization was performed by incubation at
80°C for 2 min, followed by cooling to room temperature.
Finally, real-time pyrosequencing was performed on an
automated 96-well pyrosequencer instrument with a PSQ
SNP Reagent Kit (including all required enzymes and
substrates) provided by the manufacturer (Pyrosequencing
AB). The base sequence interpretation of the chromato-
grams and SNP genotype recognition were implemented
automatically by the software and checked manually.
Results and discussion
In 153 familial non-BRCA1/BRCA2 breast cancer cases,
we found two sequence variants, 240G→A in the 5′
untranslated region and 1455C→T (S388S) in exon 4.
Each variant was identified in four cases (4 of 153; 2.6%).
The method used for studying this gene was selected to
minimize the risk of missing a mutation for technical
reasons. The DHPLC technique is known to be very
sensitive; the fragment length and optimal conditions for
the DHPLC assay were carefully designed and the RNA
template used was expressed in sufficient amounts. Thus,
the low mutation frequency obtained in the present study
is not due to the methods used.
The 240G→A alteration was identified in 12 of 186 normal
controls (6.5%), and the 1455C→T alteration in 10 of 188
normal controls (5.3%). Each variant had similar
prevalences in controls and in familial breast cancer cases
(P = 0.10 and P = 0.21, respectively; χ2 test).
In addition, both variants were found to occur together in
three of the cases. They might be in linkage disequilibrium
and constitute a haplotype on the same chromosome.
Alternatively, they might be on two different chromosomes.
If so, they could each contribute a causative effect, acting
in a recessive mode, and the concurrence of the two
variants should be observed more often in familial cases
than in normal controls as a result of genetic selection. On
examining the normal controls, 10 of the 12 individuals
with sequence alteration turned out to be carriers of both
the variants, which was similar to the familial cases. Thus,
these two variants were most probably inherited together
on the same chromosome – that is, in linkage dis-
equilibrium – in most breast cancer cases and controls.
The concurrence of the two variants is not caused by
genetic selection, and accordingly both the variants are
considered non-pathogenic.
Conclusion
The present study suggests that germline mutations in the
CTCF gene are not important as a risk factor in familial
breast cancer. However, the CTCF gene could still have a
role in cancer development. A tumour-specific truncating
14 base pair insertion in the CTCF gene was recently
identified in one invasive ductal breast cancer case. The
mutation resulted in silencing of the wild-type allele and
loss of protein expression [17]. Moreover, CTCF is likely
to participate in loss of imprinting of the gene encoding
insulin-like growth factor II (IGF2) in colorectal cancer and
Wilms tumours [18,19]. Further studies are therefore
needed to elucidate the role of CTCF in breast cancer.
Available online http://breast-cancer-research.com/content/6/3/R187
Table 1
List of the primers used for amplification and cycle sequencing in the polymerase chain reaction
Fragments Sense (5′–3′) positions of primersa Antisense (5′–3′) positions of primers Size (bp)
1 162GGAGAATGATTACGGACCTG181 622CTATGTTTATGGGCTGTTCCTC601 461
2 519AGTAATGGAGGGCACAGTG537 1017CGCATTAACCTCTGATAGCA998 499
3 940GAGGGCAAAGATGTAGATGTG960 1415CCAGTATGAGAGCGAATGTGA1395 476
4 1366GCCAGTGTAGAAGTCAGCAA1385 1811TCCTGTCTACAAGCGTAATCA1791 446
5 1768AAGCGCTTTAAGTGTGACCAG1788 2184TTCTACGGCAGGCTCCTC2167 417
6 2044GGGGAAAAGGAGGAGAA2061 2520TAAACACAGCCCAGAGAAGTC2500 477
aPosition according to GenBank reference cDNA sequence NM_006565. bp, base pairs.
Table 2
List of the primers used for pyrosequencing
Exons Sense (5′–3′) positions of primersa Antisense (5′–3′) positions of primersb Sequencing positions of primers
5′ UTR 188AAGAACAAGATGCGCTAG205 Biotin-259CTCCGTGGCTGCAAAGTCAGTT280 216GCTGACCAGGGGCTTGAGAGCTGGG239
4 723TCACATTCGCTCTCATACTGG742 Biotin-968CGGAGAAGCATTATCAATTC949 758AGTGCAGTTTGTGCAGTTATGC779
aPosition according to GenBank reference cDNA sequence NM_006565. bPosition according to GenBank reference DNA sequence AF145470.
UTR, untranslated region.Competing interests
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